Dal-Outcomes II

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Stage: klaar
Medicine: dalcetrapib
Population: ASCVD
Phase: III
First Patient In: 1 September 2011
Last Patient In: -
Last Patient Last Visit: -

Study Director

dr. E. Ronner

Cardioloog